Artiva Taps Autoimmune Expert Dr. Subhashis Banerjee as New CMO to Drive AlloNK® Forward

Artiva Biotherapeutics has named Dr Subhashis Banerjee as its new Chief Medical Officer, signalling a strategic move to deepen its focus on autoimmune diseases. Dr Banerjee, a seasoned rheumatologist and immunologist, brings over two decades of clinical development expertise, having played a major role in the advancement of blockbuster therapies like Humira®, Taltz®, and Orencia®. With his appointment, Artiva is doubling down on its AlloNK® programme, aiming to make effective, community-deliverable NK cell therapies a reality for patients with devastating autoimmune conditions.

Dr Banerjee expressed enthusiasm about joining a company pioneering next-gen NK cell therapies, emphasising the transformative potential of AlloNK’s B-cell depletion strategy in autoimmune care. Artiva’s CEO, Dr Fred Aslan, welcomed him by highlighting the unmatched experience he brings and the momentum it will add to their autoimmune ambitions. As Artiva evolves, the continued involvement of outgoing CMO Dr Thorsten Graef as a strategic advisor ensures strong continuity as the company advances toward late-stage development.